Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Breakfast News - Crusader Resources

Breakfast News - Crusader Resources

Small Cap Breakfast

Set menu

AIM:

Total number of AIM Companies (Incl Susp):

947*

Total number of AIM Companies trading:

898* 

*as at close of business 12 April 2018

Standard List**  of Main Market:

Total number of Standard List Companies

(Incl Susp):

136*

Total number of Standard List Companies trading:

123*

*as at close of business 12 April 2018

 

NEX Growth Market:

Total number of NEX Growth Market Companies (Incl Susp):

87*

Total number of NEX Growth Market Companies trading:

85*                

*as at close of business  12 April 2018

                                *A corporate client of Hybridan LLP

**  Standard Listing as defined by Hybridan LLP to be a business with strictly operational activity

                       

Dish of the day

Crusader Resources (AIM:CAS), the independent gold explorer and developer,  has raised A$6.5m at A$0.055  The Company's most advanced project, Borborema, is operationally de-risked, has a JORC reserve of 1.61 million ounces of gold at 1.18 g/t with plans to complete a BFS by the end of 2018; 

Off the menu    

Infinity Energy has cancelled it securities from trading on AIM pursuant to AIM Rule 41

Ambrian PLC has cancelled it securities from trading on AIM pursuant to AIM Rule 1

 

What’s cooking in the IPO kitchen?

AIM

KRM22, a closed-ended investment company with a particular focus on risk management in capital markets, is looking to join AIM. Offer tbc, expected 30 April 2018

Main Market Premium Listing

Avast, global cybersecurity provider with 435m users worldwide. In 2017, the Group's Adjusted Billings was $811 million, Adjusted Revenue was $780 million, Adjusted Cash EBITDA was $451 million.  Seeking to raise $200m. Due in May.

Fundamentum Supported Housing REIT. Raising £150m. Focussed on UK Social Housing assets. Due 2 May

Vivo Energy—retailer and marketer of Shell-branded fuels and lubricants in Africa, Due in May. 100% secondary sell-down of existing Shares by Selling Shareholders,  No new Money. Pricing TBA

Gore Street Energy Storage Fund—Seeking to raise £100m for the purposes of investment in a diversified portfolio of utility scale energy storage projects.  Due 03 May.

Odyssean Investment Trust—Raising £100m at £1. Due 1 May. The Company will primarily invest in smaller company equities quoted on markets operated by the London Stock Exchange.

                             

Breakfast buffet

XLMedia (LON:XLM) 159p £350.3m

The “provider of digital performance marketing,  announced the acquisition of WhichBingo.co.uk, one of the leading online informational portals and comparison sites for online bingo games in the UK. Founded in 2000, WhichBingo, is an award-winning bingo review website. The site provides in-depth information on the entire UK bingo market, publishing thousands of real player reviews, alongside its own opinion, covering every brand operating across the UK online bingo sector. More recently, WhichBingo has expanded its product reach to include additional gambling content including online slots and casino content. The Acquisition represents a further addition to the Group's website portfolio, and in particular in the fully regulated UK market. The Acquisition will benefit from increased scale through the full integration into XLMedia, which  is expected to be completed within the second half of 2018.”  FYDec18E rev $108.2m, PBT $30.86m.  

 

Integumen* (LON:SKIN) SUSPENDED

Proposed all share RTO of Cellulac.

“The enlarged group will focus on biodegradable plastic ingredients, cosmetics and human grade food supplements and will have a portfolio of existing products, with high-margins in the oral care, medical and cosmetic industries. Existing Integumen cosmetic packaging, oral care consumer products and third party products can in time be replaced with biodegradable plastic materials. These drop-in replacements will be focused on existing and near to market products. Demand for these products is established and an offtake agreement worth up to $36m over five years is already in place.”

The consideration shares  will represent approximately 84% of the issued share capital, as enlarged by the Consideration Shares only. In addition, Integumen intends to raise up to £7.5m by way of an equity placing and/or debt funding.

 

Solid State (LON:SOLI) 283p £23.93m

The “manufacturer of computing, power and communications products, and value added distributor of electronic components, is pleased to announce a distribution franchise for VPT, a leading global provider of power conversion solutions for the rapid deployment of critical power systems in avionics, military and space applications.

Solid State Supplies has been chosen by VPT due to its extensive military and aerospace knowledge, its certification to AS9120, its existing industry client base and value added distribution capabilities. The franchise is for exclusive rights to UK and Ireland and includes the transfer of the existing client base.

VPT has been selling into the UK market for 18 years to a loyal client base.  Its products do not overlap with the current Solid State Supplies range giving the opportunity to develop and expand the client's reach and product representation into relevant markets.” FYMar18E rev £45.25m  and PBT £3.1m. Div 12p.

 

NetScientific (LON:NSCI) 49p £33.83m

The “transatlantic healthcare IP commercialisation group, announces that its US-based portfolio company, Vortex BioSciences, a leading liquid biopsy company, is presenting compelling new data at the American Association for Cancer Research Annual Meeting in Chicago 14 - 18 April, 2018. These studies support the use of Vortex's non-invasive technology in the characterisation of circulating tumour cells for important clinical biomarkers, namely EGFR and PD-L1, which play a pivotal role in the development and progression of certain cancer in patients with non-small cell lung cancer.”

 

Tiziana Life Science (LON:TILS) 80p £103m

The “clinical stage biotechnology company developing targeted drugs for cancer and autoimmune diseases, announces that it has entered into an exclusive license agreement for novel technology discovered by Dr Howard Weiner at the Brigham and Women's Hospital ("BWH"), Harvard Medical School. “ Highlights of this novel technology include:

Data from animal studies demonstrate proof-of-concept of nasal administration of foralumab, a fully human anti-CD3 mAb, for treatment of neurodegenerative diseases such as Lou Gehrig's disease (ALS), progressive multiple sclerosis and traumatic brain injury.

An Investigational New Drug (IND) application for the first-in-human (FIH) evaluation of nasal administration of foralumab in healthy volunteers will be submitted shortly.

 

Frontera Resources (LON:FRR) 0.5p £79.12m

“The European focused independent oil and gas exploration and production company, notes the recent media speculation in respect to arbitration and potential territory relinquishment. The Company confirms that it has received a request for arbitration from Georgian Oil and Gas Corporation and State Agency of Oil and Gas in respect to certain terms of the Company's production sharing contract ("PSC") in Georgia, however, the full statement of the case has not been submitted and the timings for any such hearing, should it occur, are unknown.”  The Company considers the Request to be without merit and has engaged legal counsel to protect its rights. The Company intends, if the administrative formalities are followed through and the statement is submitted by the authors of the Request, to respond to each point and ensure that the Company's rights are protected. The Company is confident of its standing and complete compliance with the PSC.   

 

Columbus Energy Resources  (LON:CERP) 5.1p £33.1m

Update about the potential acquisition of a 50% interest in the Icacos field, in the South West Peninsula of Trinidad. “Whilst the transaction is still subject to a definitive sale and purchase agreement and certain regulatory approvals, the Company is confident it can work with Touchstone to complete the relevant paperwork and take over operatorship in Q2 2018.”

The consideration for the transaction is $0.5m for Primera's current net 11 bopd. However, LTL will not pay any upfront consideration for the purchase but will pay the consideration over time until 1 Jan 2021 through Primera receiving the net revenue it would have received had it retained its interest. Primera will also receive, in the event of increased production, 25% of any net revenue above the current baseline. 

 

First Property Group (LON:FPO) 49.5p £55.06m

“The property fund manager and investor with operations in the United Kingdom and Central Europe,  announced that its profit before tax for the year to 31 March 2018 is expected to be in line with market expectations.

Funds under management at the year-end amounted to £625m (2017: £477m), an increase of 31% from the prior year. Of this some £454m was held for clients (2017: £313m), an increase of 45% from the prior year. Almost all of this increase resulted from new property investments in the United Kingdom.

The Group's Preliminary results for the year to 31 March 2018 are scheduled to be announced on 8 June 2018.” 

FY Mar18E rev £24.2m and PBT £9.1m. Div 1.62p.

 

Itaconix (LON:ITX) 5.25p £4.13m

Q1 update from the innovator in sustainable performance polymers. Revenue £149k from £138k. Cash £2.5m from £6.9m.

"The start of 2018 has seen a growing number of active customers across a variety of application areas, geographies and products. This is beginning to lead to revenue growth, albeit moderate currently, as each product gains traction and markets become more familiar with the benefits of each product in terms of performance, cost and sustainability. The Board is confident, subject to the availability of further funding, that the Company is well positioned to continue to deliver revenue growth through 2018 in line with expectations."

FYDec18E £1.2m, Pre-tax loss £4.5m.

 

Fox Marble (LON:FOX) 9p £19.36m

“The company focused on marble quarrying and finishing in Kosovo and the Balkans region, announced that it has installed a new state-of-the-art Computer Numerical Control ("CNC") machine and a block vacuum pump machine in the Company's processing factory in Pristine, Kosovo. These additions to the new marble processing factory will provide additional capacity to meet increased order flow and improve margins.

 

The brand new, CNC machine is capable of automatically processing many varied shapes of material from slabs and small blocks, including 1,500 square metres of marble tiles per day. The machine is fully operational and has just manufactured the Company's first order in which the whole process has been completed in house for "cut-to-size" tiles.” FYDec 18E rev £7.8m and EBITDA £3.93m. 

Hybridan LLP Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor. The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such. Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document. This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, does not constitute  “independent investment research” for the purposes of the Financial Services Authority (FSA) rules. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, directors, officers  and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments. In the UK, this document is directed at and is for distribution only to persons who (i) fall within Article 19(5) (persons who have professional experience in matters relating to investments) or Article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) or (ii) are Professional Clients or Eligible Counterparties (as those terms are defined in the rules of the FSA) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as “relevant persons”). This document must not be acted on or relied up on by persons who are not relevant persons.  For the purposes of clarity, this document is not intended for and should not be relied upon by persons who would be classified as Retail Clients (as defined by the rules of the FSA). Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of UK or US securities law, or the law of any such other jurisdictions. Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, directors, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests. Neither the whole nor any part of this document may be duplicated in any form or by any means. Neither should this document, or any part thereof, be redistributed or disclosed to anyone without the prior consent of Hybridan LLP. Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Services Authority and is a member of the London Stock Exchange.  Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

 

Proactive Investors Limited Disclaimer

 

No investment advice

The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

 

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use